<p>深圳，2026 年 4 月 23 日 -（ACN Newswire）- 中国医疗系统控股有限公司（&#34;集团&#34;或&#34;CMS&#34;）欣然宣布，针对 MG-K10（通用名：Comekibart 注射液，&#34;MG-K10&#34;或&#34;产品&#34;）的季节性过敏性鼻炎（SAR）适应症的中国新药申请（NDA）已于 2026 年 4 月 23 日获得中国国家药品监督管理局（NMPA）的受理。该产品是一种 1 类创新药物，抗 IL-4Ra 人源化单克隆抗体注射剂，集团拥有共同开发权（不包括特应性皮炎（AD）适应症）和独占商业化权利。该产品旨在治疗中度至重度季节性过敏性鼻炎的成年患者，这些患者在使用鼻用皮质类固醇治疗后症状仍未得到有效控制。</p>
<p>NDA 的受理标志着集团眼科业务 CMS Vision 的重要里程碑，因为它将治疗重点从眼科扩展到耳鼻喉科（ENT）领域。这也标志着集团在 2 型炎症性疾病研究与开发进展中的另一个重要里程碑。如果该产品成功获得市场批准，集团将利用其强大的学术推广能力和广泛的商业化网络，加速该产品的商业化。预计这还将进一步增强 CMS Vision 在相关专业领域的学术品牌影响力，并为集团的业务增长提供新的动力。</p>
<p>BIC 潜力：每 4 周给药一次；III 期研究达到了主要终点，安全性良好</p>
<p>MG-K10 是一种创新的长效抗 IL-4Ra 人源化单克隆抗体，能够同时阻断关键的 2 型炎症细胞因子 IL-4 和 IL-13 的信号通路，从而发挥免疫调节作用。该药物正在开发用于治疗 2 型炎症性疾病，包括季节性过敏性鼻炎、哮喘、特应性皮炎（AD）、结节性瘙痒、慢性阻塞性肺病（COPD）、慢性自发性荨麻疹（CSU）、伴鼻息肉的慢性鼻窦炎和嗜酸性食管炎。目前市场上的抗 IL-4Ra 疗法需要每两周给药一次。MG-K10 具有更长的半衰期，能够实现每 4 周给药一次。因此，它有潜力成为全球首个上市的长效抗 IL-4Ra 单克隆抗体，可能成为同类最佳。MG-K10 在一项针对中度至重度季节性过敏性鼻炎成年患者的多中心、随机、双盲、安慰剂对照的 III 期临床试验中达到了主要终点。III 期研究的结果表明，主要终点达到了统计学显著性，与安慰剂组相比，疗效显著优越，且安全性良好。</p>
<p>关注未满足的需求：约 2.5 亿患者；62% 的中度至重度患者未得到有效控制；长效突破带来新的治疗机会</p>
<p>过敏性鼻炎是一种由 IgE 介导的鼻粘膜慢性炎症性疾病，其核心致病机制为 2 型炎症。它在易感个体中因接触花粉和尘螨等环境过敏原而发生。近年来，中国该疾病的患病率从 11.1% 上升至 17.6%，影响约 2.5 亿人 [1]，其中 52.2% 为持续性中度至重度患者 [2]。该疾病负担显著，已成为一个重要的公共卫生问题。目前的标准治疗，包括鼻用皮质类固醇和抗组胺药，存在明显的局限性。62% 的中度至重度患者未得到有效控制 [3]。长期使用鼻用皮质类固醇可能导致不良反应，如鼻出血 [4]，而抗组胺药常常伴随嗜睡等副作用 [5]，这表明临床需求显著未得到满足。作为一种针对 IL-4Ra 的生物治疗，MG-K10 可以从源头阻断 2 型炎症通路。与目前批准的针对同一通路的生物制剂（需要每两周给药一次）相比，MG-K10 在给药频率上实现了差异化突破，其长效特性允许每 4 周给药一次，从而显著延长了给药间隔。这可能有助于改善患者的治疗依从性，减少频繁就医所带来的时间和经济负担。该产品有潜力为对常规疗法反应不佳的中度至重度患者提供新的治疗选择，从而减轻与该疾病相关的个人和社会经济负担。</p>
<p>2025 年 1 月 24 日，集团通过其子公司与湖南玛贝克生物科技有限公司及其子公司签署了合作协议（&#34;协议&#34;），涉及 MG-K10。根据协议及补充协议，集团已获得该产品在中国大陆、香港特别行政区、澳门特别行政区、台湾地区和新加坡的共同开发权（不包括 AD）和独占商业化权利；其子公司 Dermavon Holdings Limited 通过其子公司获得了该产品在中国大陆皮肤科适应症领域的共同开发权（不包括 AD）和独占商业化权利。</p>
<p>关于 CMS</p>
<p>CMS 是一家将制药创新与商业化相结合的平台公司，具备强大的产品生命周期管理能力，致力于提供具有竞争力的产品和服务，以满足未满足的医疗需求。</p>
<p>CMS 专注于全球首创（FIC）和最佳（BIC）创新产品，高效推动创新产品的临床研究、开发和商业化，实现科学研究向临床实践的持续转化，以造福患者。</p>
<p>CMS 深入参与多个专业治疗领域，已建立了成熟的商业化能力、广泛的网络和专家资源，使其主要上市产品在学术和市场上占据领先地位。CMS 持续推动其优势专业领域的深入发展，增强心血管 - 肾脏 - 代谢/胃肠病/眼科/皮肤健康业务的竞争力，带来专业领域的规模经济。其中，皮肤健康业务（Dermavon）已成为该领域的领先企业，并计划在香港联合交易所独立上市。同时，CMS 持续推动其在东南亚和中东的综合研发、制造和商业化链的运营与发展，把握新兴市场的增长机会，支持集团的高质量和可持续发展。</p>
<p>参考文献</p>
<p>1. Cheng L, Chen J, Fu Q, 等. 中国过敏学会过敏性鼻炎诊断与治疗指南. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
<p>2. Zheng, Ming 等. &#34;中国 13 个大城市过敏性鼻炎患者的临床特征.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
<p>3. White, P 等. &#34;英国普通实践中花粉症患者的症状控制：我们做得怎么样，是否需要过敏原免疫治疗？&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
<p>4. Rosenblut, A 等. &#34;氟替卡松呋喃鼻喷雾剂在成人和青少年中的长期安全性研究。&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
<p>5. Bernstein, Jonathan A 等. &#34;过敏性鼻炎：综述。&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
<p>CMS 免责声明及前瞻性声明</p>
<p>本新闻稿并不旨在向您推广任何产品，也不用于广告目的。本新闻稿不推荐任何药物、医疗器械和/或适应症。如果您想了解特定疾病的诊断和治疗，请遵循您的医生或其他医疗健康专业人士的意见或指导。医疗专业人士所做的任何治疗相关决策应基于患者的具体情况，并符合药品说明书。</p>
<p>本新闻稿由 CMS 准备，并不构成任何购买或认购任何证券的要约或邀请，也不应作为任何合同或具有约束力的承诺的基础或依赖。此新闻稿是基于 CMS 认为可靠的信息和数据准备的，但 CMS 不作任何明示或暗示的陈述或保证，且不应依赖于本新闻稿内容的真实性、准确性、完整性、公平性和合理性。此新闻稿中讨论的某些事项可能包含关于集团市场机会和商业前景的声明，这些声明单独或共同构成前瞻性声明。此类前瞻性声明并不保证未来的表现，并且受到已知和未知的风险、不确定性和假设的影响，这些因素难以预测。此新闻稿中包含的第三方所作的任何前瞻性声明和预测不被集团采纳，且公司对这些第三方声明和预测不承担责任。</p>
<p>媒体联系</p>
<p>品牌：中国医疗系统控股有限公司。</p>
<p>联系人：CMS 投资者关系</p>
<p>电子邮件：ir@cms.net.cn</p>
<p>网站：https://web.cms.net.cn/en/home/</p>
<p>来源：中国医疗系统控股有限公司</p>
<p>版权 © 2026 ACN Newswire . 保留所有权利。</p>

<p>中国医疗系统控股有限公司（CMS）宣布，其创新药物 MG-K10 的新药申请（NDA）已被中国国家药品监督管理局接受。该药物也被称为 Comekibart 注射液，旨在治疗中度至重度的季节性过敏性鼻炎（SAR），适用于使用鼻用皮质类固醇治疗效果不佳的成年人。CMS 拥有 MG-K10 的独家商业化权利，但不包括其在特应性皮炎中的使用</p>

<p>SHENZHEN, Apr 23, 2026 - (ACN Newswire) - China Medical System Holdings Limited (the &#34;Group&#34; or &#34;CMS&#34;) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, &#34;MG-K10&#34; or the &#34;Product&#34;), a Class 1 innovative drug anti-IL-4Ra humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.</p>
<div class="lb-trans"><p>深圳，2026 年 4 月 23 日 -（ACN Newswire）- 中国医疗系统控股有限公司（&#34;集团&#34;或&#34;CMS&#34;）欣然宣布，针对 MG-K10（通用名：Comekibart 注射液，&#34;MG-K10&#34;或&#34;产品&#34;）的季节性过敏性鼻炎（SAR）适应症的中国新药申请（NDA）已于 2026 年 4 月 23 日获得中国国家药品监督管理局（NMPA）的受理。该产品是一种 1 类创新药物，抗 IL-4Ra 人源化单克隆抗体注射剂，集团拥有共同开发权（不包括特应性皮炎（AD）适应症）和独占商业化权利。该产品旨在治疗中度至重度季节性过敏性鼻炎的成年患者，这些患者在使用鼻用皮质类固醇治疗后症状仍未得到有效控制。</p>
</div><p>The acceptance of the NDA represents an important milestone for the Group's ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group's research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group's business growth.</p>
<div class="lb-trans"><p>NDA 的受理标志着集团眼科业务 CMS Vision 的重要里程碑，因为它将治疗重点从眼科扩展到耳鼻喉科（ENT）领域。这也标志着集团在 2 型炎症性疾病研究与开发进展中的另一个重要里程碑。如果该产品成功获得市场批准，集团将利用其强大的学术推广能力和广泛的商业化网络，加速该产品的商业化。预计这还将进一步增强 CMS Vision 在相关专业领域的学术品牌影响力，并为集团的业务增长提供新的动力。</p>
</div><p>BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profile</p>
<div class="lb-trans"><p>BIC 潜力：每 4 周给药一次；III 期研究达到了主要终点，安全性良好</p>
</div><p>MG-K10 is an innovative long-acting anti-IL-4Ra humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Ra therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Ra monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.</p>
<div class="lb-trans"><p>MG-K10 是一种创新的长效抗 IL-4Ra 人源化单克隆抗体，能够同时阻断关键的 2 型炎症细胞因子 IL-4 和 IL-13 的信号通路，从而发挥免疫调节作用。该药物正在开发用于治疗 2 型炎症性疾病，包括季节性过敏性鼻炎、哮喘、特应性皮炎（AD）、结节性瘙痒、慢性阻塞性肺病（COPD）、慢性自发性荨麻疹（CSU）、伴鼻息肉的慢性鼻窦炎和嗜酸性食管炎。目前市场上的抗 IL-4Ra 疗法需要每两周给药一次。MG-K10 具有更长的半衰期，能够实现每 4 周给药一次。因此，它有潜力成为全球首个上市的长效抗 IL-4Ra 单克隆抗体，可能成为同类最佳。MG-K10 在一项针对中度至重度季节性过敏性鼻炎成年患者的多中心、随机、双盲、安慰剂对照的 III 期临床试验中达到了主要终点。III 期研究的结果表明，主要终点达到了统计学显著性，与安慰剂组相比，疗效显著优越，且安全性良好。</p>
</div><p>Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunities</p>
<div class="lb-trans"><p>关注未满足的需求：约 2.5 亿患者；62% 的中度至重度患者未得到有效控制；长效突破带来新的治疗机会</p>
</div><p>Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Ra, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.</p>
<div class="lb-trans"><p>过敏性鼻炎是一种由 IgE 介导的鼻粘膜慢性炎症性疾病，其核心致病机制为 2 型炎症。它在易感个体中因接触花粉和尘螨等环境过敏原而发生。近年来，中国该疾病的患病率从 11.1% 上升至 17.6%，影响约 2.5 亿人 [1]，其中 52.2% 为持续性中度至重度患者 [2]。该疾病负担显著，已成为一个重要的公共卫生问题。目前的标准治疗，包括鼻用皮质类固醇和抗组胺药，存在明显的局限性。62% 的中度至重度患者未得到有效控制 [3]。长期使用鼻用皮质类固醇可能导致不良反应，如鼻出血 [4]，而抗组胺药常常伴随嗜睡等副作用 [5]，这表明临床需求显著未得到满足。作为一种针对 IL-4Ra 的生物治疗，MG-K10 可以从源头阻断 2 型炎症通路。与目前批准的针对同一通路的生物制剂（需要每两周给药一次）相比，MG-K10 在给药频率上实现了差异化突破，其长效特性允许每 4 周给药一次，从而显著延长了给药间隔。这可能有助于改善患者的治疗依从性，减少频繁就医所带来的时间和经济负担。该产品有潜力为对常规疗法反应不佳的中度至重度患者提供新的治疗选择，从而减轻与该疾病相关的个人和社会经济负担。</p>
</div><p>On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (&#34;Agreement&#34;) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.</p>
<div class="lb-trans"><p>2025 年 1 月 24 日，集团通过其子公司与湖南玛贝克生物科技有限公司及其子公司签署了合作协议（&#34;协议&#34;），涉及 MG-K10。根据协议及补充协议，集团已获得该产品在中国大陆、香港特别行政区、澳门特别行政区、台湾地区和新加坡的共同开发权（不包括 AD）和独占商业化权利；其子公司 Dermavon Holdings Limited 通过其子公司获得了该产品在中国大陆皮肤科适应症领域的共同开发权（不包括 AD）和独占商业化权利。</p>
</div><p>About CMS</p>
<div class="lb-trans"><p>关于 CMS</p>
</div><p>CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.</p>
<div class="lb-trans"><p>CMS 是一家将制药创新与商业化相结合的平台公司，具备强大的产品生命周期管理能力，致力于提供具有竞争力的产品和服务，以满足未满足的医疗需求。</p>
</div><p>CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.</p>
<div class="lb-trans"><p>CMS 专注于全球首创（FIC）和最佳（BIC）创新产品，高效推动创新产品的临床研究、开发和商业化，实现科学研究向临床实践的持续转化，以造福患者。</p>
</div><p>CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&amp;D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.</p>
<div class="lb-trans"><p>CMS 深入参与多个专业治疗领域，已建立了成熟的商业化能力、广泛的网络和专家资源，使其主要上市产品在学术和市场上占据领先地位。CMS 持续推动其优势专业领域的深入发展，增强心血管 - 肾脏 - 代谢/胃肠病/眼科/皮肤健康业务的竞争力，带来专业领域的规模经济。其中，皮肤健康业务（Dermavon）已成为该领域的领先企业，并计划在香港联合交易所独立上市。同时，CMS 持续推动其在东南亚和中东的综合研发、制造和商业化链的运营与发展，把握新兴市场的增长机会，支持集团的高质量和可持续发展。</p>
</div><p>Reference</p>
<div class="lb-trans"><p>参考文献</p>
</div><p>1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
<div class="lb-trans"><p>1. Cheng L, Chen J, Fu Q, 等. 中国过敏学会过敏性鼻炎诊断与治疗指南. Allergy Asthma Immunol Res. 2018;10:300‑353.</p>
</div><p>2. Zheng, Ming et al. &#34;Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
<div class="lb-trans"><p>2. Zheng, Ming 等. &#34;中国 13 个大城市过敏性鼻炎患者的临床特征.&#34; Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561</p>
</div><p>3. White, P et al. &#34;Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
<div class="lb-trans"><p>3. White, P 等. &#34;英国普通实践中花粉症患者的症状控制：我们做得怎么样，是否需要过敏原免疫治疗？&#34; Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x</p>
</div><p>4. Rosenblut, A et al. &#34;Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
<div class="lb-trans"><p>4. Rosenblut, A 等. &#34;氟替卡松呋喃鼻喷雾剂在成人和青少年中的长期安全性研究。&#34; Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x</p>
</div><p>5. Bernstein, Jonathan A et al. &#34;Allergic Rhinitis: A Review.&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
<div class="lb-trans"><p>5. Bernstein, Jonathan A 等. &#34;过敏性鼻炎：综述。&#34; JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530</p>
</div><p>CMS Disclaimer and Forward-Looking Statements</p>
<div class="lb-trans"><p>CMS 免责声明及前瞻性声明</p>
</div><p>This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug package insert.</p>
<div class="lb-trans"><p>本新闻稿并不旨在向您推广任何产品，也不用于广告目的。本新闻稿不推荐任何药物、医疗器械和/或适应症。如果您想了解特定疾病的诊断和治疗，请遵循您的医生或其他医疗健康专业人士的意见或指导。医疗专业人士所做的任何治疗相关决策应基于患者的具体情况，并符合药品说明书。</p>
</div><p>This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.</p>
<div class="lb-trans"><p>本新闻稿由 CMS 准备，并不构成任何购买或认购任何证券的要约或邀请，也不应作为任何合同或具有约束力的承诺的基础或依赖。此新闻稿是基于 CMS 认为可靠的信息和数据准备的，但 CMS 不作任何明示或暗示的陈述或保证，且不应依赖于本新闻稿内容的真实性、准确性、完整性、公平性和合理性。此新闻稿中讨论的某些事项可能包含关于集团市场机会和商业前景的声明，这些声明单独或共同构成前瞻性声明。此类前瞻性声明并不保证未来的表现，并且受到已知和未知的风险、不确定性和假设的影响，这些因素难以预测。此新闻稿中包含的第三方所作的任何前瞻性声明和预测不被集团采纳，且公司对这些第三方声明和预测不承担责任。</p>
</div><p>Media Contact</p>
<div class="lb-trans"><p>媒体联系</p>
</div><p>Brand: China Medical System Holdings Ltd.</p>
<div class="lb-trans"><p>品牌：中国医疗系统控股有限公司。</p>
</div><p>Contact: CMS Investor Relations</p>
<div class="lb-trans"><p>联系人：CMS 投资者关系</p>
</div><p>Email: ir@cms.net.cn</p>
<div class="lb-trans"><p>电子邮件：ir@cms.net.cn</p>
</div><p>Website: https://web.cms.net.cn/en/home/</p>
<div class="lb-trans"><p>网站：https://web.cms.net.cn/en/home/</p>
</div><p>Source: China Medical System Holdings Limited</p>
<div class="lb-trans"><p>来源：中国医疗系统控股有限公司</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 © 2026 ACN Newswire . 保留所有权利。</p>
</div>

CMS; 8A8.SG): 1 类创新药 MG-K10 用于季节性过敏性鼻炎的上市申请在中国已被受理